17 / 18
7
t h
E u r o p e a n C o n g r e s s o n
Obesity and
Eating Disorder
Obesity 2018
Journal of Obesity & Eating Disorders
ISSN 2471-8203
A p r i l 1 2 - 1 3 , 2 0 1 8
Am s t e r d a m , N e t h e r l a n d s
Page 59
B
inge eating disorder (BED) and bulimia nervosa (BN) are
characterised by recurrent episodes of binge (uncontrolled
overeating) and (in BN) by extreme weight control behaviours
such as fasting to compensate for the binge eating. BED and
BN are the commonest eating disorders in the community
and are associated with poor mental and physical health,
including obesity and metabolic disorder. Further, the rate of
recurrent binge eating and fasting/severe dietary restriction
are increasing in the general population and since 1995 have
increased most, 7 to 11-fold, in Australians with comorbid
obesity. Current standard care, cognitive behaviour therapy
(CBT) however, results in poor recovery or abstinence from
binge eating in a large proportion of people with BN and BED,
and fails to address this important co-morbidity, overweight
or obesity. We have developed an integrated therapy for
BED comorbid with obesity, namely, a healthy approach to
weight management and food in eating disorders (HAPIFED).
HAPIFED is designed to integrate CBT for BN/BED with
behavioural weight loss approaches and (unlike standard
CBT) to be multidisciplinary. HAPIFED introduces approaches
that address healthy lifestyle changes and appetite awareness
with the aim of reducing eating as a means of emotion
regulation. It allows reduced energy intake and education
around specific food choices – a necessary element in
weight management. In a phase 2 feasibility study, 8 of 11
participants with BED/BN completed a group-based HAPIFED.
Participants reported improved eating disorder symptoms, 6
had modest reductions in weight, and all rated the suitability
New approaches to the challenge of obesity
co-morbid with an eating disorder
Phillipa J Hay
Western Sydney University, Australia
J Obes Eat Disord 2018, Volume: 4
DOI: 10.21767/2471-8203-C1-009
and success of HAPIFED highly. This presentation will
discuss the further testing and development of HAPIFED for
co-morbid obesity and eating disorders and the role of other
new approaches including cognitive remediation therapy
and medications.
p.hay@westernsydney.edu.au